Literature DB >> 34121236

Cell/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy.

Hong Pan1, Mingbin Zheng1,2, Aiqing Ma1, Lanlan Liu1, Lintao Cai1.   

Abstract

Numerous clinical trials for cancer precision medicine research are limited due to the drug resistance, side effects, and low efficacy. Unsatisfactory outcomes are often caused by complex physiologic barriers and abnormal immune events in tumors, such as tumor target alterations and immunosuppression. Cell/bacteria-derived materials with unique bioactive properties have emerged as attractive tools for personalized therapy in cancer. Naturally derived bioactive materials, such as cell and bacterial therapeutic agents with native tropism or good biocompatibility, can precisely target tumors and effectively modulate immune microenvironments to inhibit tumors. Here, the recent advances in the development of cell/bacteria-based bioactive materials for immune modulation and precision therapy in cancer are summarized. Cell/bacterial constituents, including cell membranes, bacterial vesicles, and other active substances have inherited their unique targeting properties and antitumor capabilities. Strategies for engineering living cell/bacteria to overcome complex biological barriers and immunosuppression to promote antitumor efficacy are also summarized. Moreover, past and ongoing trials involving personalized bioactive materials and promising agents such as cell/bacteria-based micro/nano-biorobotics are further discussed, which may become another powerful tool for treatment in the near future.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  cell/bacteria bioactive materials; immunomodulation; living drug; micro/nano-biorobotics; precise therapy; targeting delivery

Mesh:

Year:  2021        PMID: 34121236     DOI: 10.1002/adma.202100241

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  6 in total

Review 1.  Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology.

Authors:  Víctor M Moreno; Alejandro Baeza
Journal:  Pharmaceutics       Date:  2022-04-03       Impact factor: 6.525

2.  Erythrocyte membrane-camouflaged nanoparticles as effective and biocompatible platform: Either autologous or allogeneic erythrocyte-derived.

Authors:  Jun Dai; Zhaojun Chen; Shixuan Wang; Fan Xia; Xiaoding Lou
Journal:  Mater Today Bio       Date:  2022-05-05

3.  Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.

Authors:  Yunhao Wang; Qingfu Zhao; Binyu Zhao; Youshi Zheng; Qiuyu Zhuang; Naishun Liao; Peiyuan Wang; Zhixiong Cai; Da Zhang; Yongyi Zeng; Xiaolong Liu
Journal:  Adv Sci (Weinh)       Date:  2022-02-10       Impact factor: 16.806

Review 4.  Tumor microbiome metabolism: A game changer in cancer development and therapy.

Authors:  Xiaozhuang Zhou; Shruthi Kandalai; Farzana Hossain; Qingfei Zheng
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

Review 5.  Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives.

Authors:  Yongkang Lai; Wei Wei; Yiqi Du; Jie Gao; Zhaoshen Li
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 6.  Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy.

Authors:  Han Liu; Hao Zhang; Yafei Han; Yan Hu; Zhen Geng; Jiacan Su
Journal:  Theranostics       Date:  2022-09-11       Impact factor: 11.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.